InsiderClue
← All stocks

Dianthus Therapeutics, Inc. /DE/

DNTH Scheduled selling only
CIK 0001690585 #1220 in the set updated 21 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$71.20M
$0.00 on a plan · $71.20M straight out of an exercise
Sold at will
$0.00
0 of 66 sales
Net
−$71.20M
$0.00 against sales at will

By person

9 insiders · 69 transactions
10.8×

Marino Garcia holds 10.8 times base salary in stock. $6.82M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $104.39, the price Common Stock was last bought or sold at on the open market here, on 17 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Garcia Marino
CEO AND PRESIDENT
—
$27.96M (12) scheduled
−$27.96M
65,292
0.1167%
$6.82M
—
Randhawa Simrat
EVP, Head of R&D
—
$15.00M (11) scheduled
−$15.00M
4,000
0.0072%
$417.56K
0.0%
Savitz Ryan
EVP, CFO & CBO
—
$14.29M (13) scheduled
−$14.29M
0
0.0000%
$0.00
—
CARR EDWARD
CHIEF ACCOUNTING OFFICER
—
$5.59M (10) scheduled
−$5.59M
0
0.0000%
$0.00
—
Veness Adam M
SVP, General Counsel and Sec.
—
$4.63M (5) scheduled
−$4.63M
15,000
0.0268%
$1.57M
—
Soteropoulos Paula
Director
—
$2.25M (3) scheduled
−$2.25M
0
0.0000%
$0.00
—
McGeorge Anne
Director
—
$844.82K (5) scheduled
−$844.82K
0
0.0000%
$0.00
—
Read Simon
Director
—
$630.79K (7) scheduled
−$630.79K
0
0.0000%
$0.00
—
Fairmount Funds Management LLC entity
Director
—
—
—
0
0.0000%
$0.00
−100.0%

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Veness Adam M
13 Aug 2026
SVP, General Counsel and Sec.
Exercised, kept
15,000
$18.17
$272.55K
Garcia Marino
16 Mar 2026
CEO AND PRESIDENT
Exercised, kept
5,592
$17.88
$99.98K
Garcia Marino
16 Mar 2026
CEO AND PRESIDENT
Exercised, kept
59,700
$6.70
$399.99K
Show all 69 transactions →

What was left out

Form 4 filings counted 37
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 66
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 978,851
History held since 27 Jun 2018